Priorities for a New FDA | Martin Makary, Vinay Prasad (Jun 2025) Article

[Michael Harrop]

https://jamanetwork.com/journals/jama/fullarticle/2835314

Why does it take more than 10 years for a new drug to come to market? Why are childhood chronic diseases so prevalent? And how can regulators adapt to meet the challenges facing clinicians today? These questions are at the forefront for the US Food and Drug Administration (FDA).

At the FDA, we will examine the role of ultraprocessed foods, food additives, and environmental toxins

We will rapidly usher to market new products with transformational potential.

To reinvigorate innovation, we must become a user-friendly FDA that partners with industry rather than takes a receive-only posture. At the same time, the FDA will guard against a cozy relationship that has characterized the agency in the past and led to allegations of industry capture.

Click to shrink...

Subsections:

• Unleashing AI
• Healthier Food for Children
• Harnessing Big Data
• Financial Toxicity

In summary, the FDA will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children, and common-sense approaches to rebuild the public trust.

Click to shrink...

Sounds like more useless, distracting BS, and that they have no plans to do anything about FMT.